Roche’s sales of ranibizumab (Lucentis), already depleted by competition from such products as afilbercept (Eylea), face upcoming erosion from biosimilar competition.
Roche’s sales of ranibizumab (Lucentis), already depleted by competition from such products as afilbercept (Eylea), face upcoming erosion from biosimilar competition.
Ranibizumab, which is approved to treat neovascular age-related macular degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME, may not be among Roche’s biggest-selling innovator biologics. However, with $1.8 billion in sales in 2016, ranibizumab has several biosimilar developers eager to capture a share of the retina drug’s market.
Among those developers is Samsung Bioepis, which will begin a phase 3 trial for its SB11, a proposed ranibizumab biosimilar, next month. The randomized, double-masked, parallel group, multicenter study will compare the safety, efficacy, pharmacokinetics, and immunogenicity between SB11 and the reference ranibizumab in patients who have neovascular AMD. The subjects will be randomized in a 1:1 ratio to receive either a 0.5-mg intravitreal dose of SB11 or the branded Lucentis every 4 weeks. The primary outcomes measured will be the change from baseline in best corrected visual acuity at week 8 and change from baseline in central subfield thickness at week 4. Samsung Bioepis projects that it will have collected its primary outcome data by April of 2019.
Also in phase 3 development with a ranibizumab biosimilar is Formycon. The German company is currently undertaking a phase 3 trial of its FYB201 in patients with neovascular AMD. The company reports that it developed its study in consultation with both the European Medicines Agency and FDA in hopes that it will achieve regulatory approval in both markets. Formycon, which expects to have collected its primary outcome data by March of 2020, says that it hopes to launch its biosimilar immediately upon patent expiry of the reference product in Europe (2022) and in the United States (2020).
Pfenex, after having reassumed the rights to PF582 from Pfizer in 2016, is also developing a biosimilar. Indian drug maker Intas launched a “similar biologic” (Razumab) in 2015, but manufacturing issues with the drug caused ocular inflammation in approximately 10% of patients receiving the drug, leading the manufacturer to revise its production process.
Roche, meanwhile, is attempting to maintain its hold on the ranibizumab market after its product loses patent protection. The company is currently collaborating with Ascendis Pharma on a longer-acting ranibizumab that could reduce the frequency of intravitreal injections to as little as 2 times per year.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.